TY - JOUR
T1 - High prevalence of masked uncontrolled morning hypertension in elderly non-valvular atrial fibrillation patients
T2 - Home blood pressure substudy of the ANAFIE Registry
AU - Kario, Kazuomi
AU - Hasebe, Naoyuki
AU - Okumura, Ken
AU - Yamashita, Takeshi
AU - Akao, Masaharu
AU - Atarashi, Hirotsugu
AU - Ikeda, Takanori
AU - Koretsune, Yukihiro
AU - Shimizu, Wataru
AU - Tsutsui, Hiroyuki
AU - Toyoda, Kazunori
AU - Hirayama, Atsushi
AU - Yasaka, Masahiro
AU - Yamaguchi, Takenori
AU - Teramukai, Satoshi
AU - Kimura, Tetsuya
AU - Kaburagi, Jumpei
AU - Takita, Atsushi
AU - Inoue, Hiroshi
N1 - Funding Information:
This study was funded by Daiichi Sankyo Co., Ltd., Tokyo, Japan. The authors thank all individuals (physicians, nurses, institutional staff, and patients) involved in the ANAFIE Registry. They also thank IQVIA Services Japan KK and EP-CRSU for their partial support in the conduct of this Registry, and Sally-Anne Mitchell, PhD, and Keyra Martinez Dunn, MD, of Edanz Evidence Generation for providing medical writing support, which was funded by Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Funding Information:
Kazuomi Kario received research grants from Bristol‐Myers Squibb, Bayer, Daiichi Sankyo, Omron Healthcare Inc, and A&D Inc, and remuneration from Daiichi Sankyo, Bayer, and Omron Healthcare Inc. Naoyuki Hasebe received research funding from Bristol‐Myers Squibb and Daiichi Sankyo, and remuneration from Daiichi Sankyo and Bayer. Takeshi Yamashita received research funding from Bristol‐Myers Squibb, Bayer, and Daiichi Sankyo, manuscript fees from Daiichi Sankyo and Bristol‐Myers Squibb, and remuneration from Daiichi Sankyo, Bayer, Pfizer Japan, and Bristol‐Myers Squibb. Masaharu Akao received research funding from Bayer and Daiichi Sankyo, and remuneration from Bristol‐Myers Squibb, Nippon Boehringer Ingelheim, Bayer, and Daiichi Sankyo. Hirotsugu Atarashi received remuneration from Daiichi Sankyo. Takanori Ikeda received research funding from Daiichi Sankyo and Bayer, and remuneration from Daiichi Sankyo, Bayer, Nippon Boehringer Ingelheim, and Bristol‐Myers Squibb. Yukihiro Koretsune received remuneration from Daiichi Sankyo, Bayer, and Nippon Boehringer Ingelheim. Ken Okumura received remuneration from Nippon Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, and Medtronic. Wataru Shimizu received research funding from Bristol‐Myers Squibb, Daiichi Sankyo, and Nippon Boehringer Ingelheim, and patent royalties/licensing fees from Daiichi Sankyo, Pfizer Japan, Bristol‐Myers Squibb, Bayer, and Nippon Boehringer Ingelheim. Hiroyuki Tsutsui received research funding from Daiichi Sankyo, and Nippon Boehringer Ingelheim, remuneration from Daiichi Sankyo, Bayer, Nippon Boehringer Ingelheim, and Pfizer Japan, scholarship funding from Daiichi Sankyo, and consultancy fees from Pfizer Japan, Bayer, and Nippon Boehringer Ingelheim. Kazunori Toyoda and Hiroshi Inoue received remuneration from Daiichi Sankyo, Bayer, Bristol‐Myers Squibb, and Nippon Boehringer Ingelheim. Atsushi Hirayama participated in a course endowed by Boston Scientific Japan, and has received research funding from Daiichi Sankyo and Bayer, and remuneration from Bayer, Daiichi Sankyo, Bristol‐Myers Squibb, and Nippon Boehringer Ingelheim. Masahiro Yasaka received research funding from Nippon Boehringer Ingelheim, and remuneration from Nippon Boehringer Ingelheim, Daiichi Sankyo, Bayer, Bristol‐Myers Squibb, and Pfizer Japan. Takenori Yamaguchi acted as an Advisory Board member of Daiichi Sankyo, and received remuneration from Daiichi Sankyo and Bristol‐Myers Squibb. Satoshi Teramukai received research funding from Nippon Boehringer Ingelheim and remuneration from Daiichi Sankyo. Tetsuya Kimura, Jumpei Kaburagi, and Atsushi Takita are employees of Daiichi Sankyo.
Funding Information:
This study was funded by Daiichi Sankyo Co., Ltd., Tokyo, Japan. The authors thank all individuals (physicians, nurses, institutional staff, and patients) involved in the ANAFIE Registry. They also thank IQVIA Services Japan KK and EP‐CRSU for their partial support in the conduct of this Registry, and Sally‐Anne Mitchell, PhD, and Keyra Martinez Dunn, MD, of Edanz Evidence Generation for providing medical writing support, which was funded by Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Publisher Copyright:
© 2020 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.
PY - 2021/1
Y1 - 2021/1
N2 - In the ANAFIE Registry home blood pressure subcohort, we evaluated 5204 patients aged ≥75 years with non-valvular atrial fibrillation (NVAF) to assess blood pressure (BP) control, prevalence of masked hypertension, and anticoagulant use. Mean clinic (C) and home (H) systolic/diastolic BP(SBP/DBP) was 128.5/71.3 and 127.7/72.6 mm Hg, respectively. Overall, 77.5% of patients had hypertension; of these, 27.7%, 13.4%, 23.4%, and 35.6% had well-controlled, white coat, masked, and sustained hypertension, respectively. Masked hypertension prevalence increased with diabetes, decreased renal function, age ≥80 years, current smoker status, and chronic obstructive pulmonary disease. By morning/evening average, 59.0% of patients had mean H-SBP ≥ 125 mm Hg; 48.9% had mean C-SBP ≥ 130 mm Hg. Early morning hypertension (morning H-SBP ≥ 125 mm Hg) was found in 65.9% of patients. Although 51.1% of patients had well-controlled C-SBP, 52.5% of these had uncontrolled morning H-SBP. In elderly NVAF patients, morning H-BP was poorly controlled, and masked uncontrolled morning hypertension remains significant.
AB - In the ANAFIE Registry home blood pressure subcohort, we evaluated 5204 patients aged ≥75 years with non-valvular atrial fibrillation (NVAF) to assess blood pressure (BP) control, prevalence of masked hypertension, and anticoagulant use. Mean clinic (C) and home (H) systolic/diastolic BP(SBP/DBP) was 128.5/71.3 and 127.7/72.6 mm Hg, respectively. Overall, 77.5% of patients had hypertension; of these, 27.7%, 13.4%, 23.4%, and 35.6% had well-controlled, white coat, masked, and sustained hypertension, respectively. Masked hypertension prevalence increased with diabetes, decreased renal function, age ≥80 years, current smoker status, and chronic obstructive pulmonary disease. By morning/evening average, 59.0% of patients had mean H-SBP ≥ 125 mm Hg; 48.9% had mean C-SBP ≥ 130 mm Hg. Early morning hypertension (morning H-SBP ≥ 125 mm Hg) was found in 65.9% of patients. Although 51.1% of patients had well-controlled C-SBP, 52.5% of these had uncontrolled morning H-SBP. In elderly NVAF patients, morning H-BP was poorly controlled, and masked uncontrolled morning hypertension remains significant.
UR - http://www.scopus.com/inward/record.url?scp=85096690975&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096690975&partnerID=8YFLogxK
U2 - 10.1111/jch.14095
DO - 10.1111/jch.14095
M3 - Article
C2 - 33190415
AN - SCOPUS:85096690975
SN - 1524-6175
VL - 23
SP - 73
EP - 82
JO - Journal of Clinical Hypertension
JF - Journal of Clinical Hypertension
IS - 1
ER -
